AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15265250
Drug: Raloxifene 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 120 mg
Trial: 25469046
Drug: Xiaoyao pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoyao pill
Trial: 22302316
Drug: Intra-articular betamethasone
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-articular betamethasone injections (28 mg, up to four swollen joints/visit)
Trial: 19398575
Drug: Epirubicin/platinum/fluoropyrimidine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (F group)
Trial: 22773240
Drug: Octreotide long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide long-acting repeatable depot (OctLAR), maximum dose 40 mg, administered for 2 years (Year 1 and Year 2).
Trial: 22773240
Drug: Octreotide long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide long-acting repeatable depot (OctLAR), administered for 2 years (Year 1 and Year 2).
Trial: 19682194
Drug: p.o. omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. omeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h
Trial: 19682194
Drug: i.v. omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. omeprazole 80 mg followed by infusion 8 mg/h for 72 h
Trial: 19682194
Drug: p.o. pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. pantoprazole 80 mg bolus followed by 80 mg every 12 h for 72 h
Trial: 19682194
Drug: i.v. rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. rabeprazole 80 mg followed by infusion 8 mg/h for 72 h
Trial: 19682194
Drug: No proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No proton pump inhibitor treatment
Trial: 11592359
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg CII
Trial: 10346406
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose (50 ml of 50% glucose)
Trial: 26884472
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon (1 mg)
Trial: 23975860
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus medication education (access to information booklets and eight 30-min face-to-face counselling sessions over 4 weeks)
Trial: 11141388
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin (LVF), 500 mg v.o. every 24 h
Trial: 11141388
Drug: Intravenous amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amoxicillin/clavulanate (AMX/CL), 1.02 g i.v. every 8 h
Trial: 11141388
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone (CTX), 1 g i.v. every 12 h
Trial: 20934833
Drug: Intervention pharmacies
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention pharmacies received weekly updates on EC, fliers with three key messages on EC, and information, education, and communication materials.
Trial: 16536247
Drug: Narcotic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narcotic administration (as morphine equivalents)
Trial: 16536247
Drug: Initial HCAT
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial HCAT administration
Trial: 12885371
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride (RLX) 60 mg daily for 12 months
Trial: 1679661
Drug: Intravenous celiprolol
RxNorm normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous celiprolol (8 mg)
Trial: 9602984
Drug: Co-amoxiclav (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (500 mg three times daily for 10 days)
Trial: 8011967
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone dose of 0.8 mg kg‐1
Trial: 8011967
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone dose of 0.66 mg kg‐1
Trial: 25346460
Drug: Propofol (6-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (6-8 mg/kg/h)
Trial: 23272985
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment strategy (including pharmacological and non-pharmacological therapy)
Trial: 21489819
Drug: Medical standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical standard therapy (physiotherapy)
Trial: 16420547
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (mostly semisynthetic penicillin)
Trial: 31899823
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 6 months
Trial: 28650326
Drug: CofNovex plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CofNovex plus (EMA) syrup
Trial: 16505650
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/day, group A)
Trial: 12926583
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm (T)
Trial: 10856536
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg fluvastatin alone
Trial: 10856536
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg fluvastatin + 400 mg bezafibrate
Trial: 24783914
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg twice weekly) with background Methotrexate
Trial: 20367669
Drug: APS 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APS 5% lotion
Trial: 15818486
Drug: Innovative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative treatment (directly from step I to step III of the WHO analgesic ladder)
Trial: 15818486
Drug: Innovative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative treatment
Trial: 12014724
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day tegaserod
Trial: 12014724
Drug: 12 mg/day
RxNorm normalized name: EMSAM 12 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/day tegaserod
Trial: 9599499
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for six weeks
Trial: 8025768
Drug: UK,74505 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK,74505 25 mg
Trial: 8025768
Drug: UK,74505 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK,74505 100 mg
Trial: 2663343
Drug: 7‐mono‐hydroxyethylrutoside and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐mono‐hydroxyethylrutoside and acetylsalicylic acid combination
Trial: 23313654
Drug: Tdap-IPV and
RxNorm normalized name: acellular pertussis vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap-IPV and inactivated influenza vaccine administered concomitantly (Group 1)
Trial: 16468062
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone (NAL) 0.1 mg kg(‐1)
Trial: 9373790
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial chemotherapy using implanted reservoirs (Epirubicin 40 mg/m2 every month)
Trial: 9373790
Drug: Conventional transcatheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional transcatheter arterial chemotherapy (Epirubicin 60 mg/m2 every 3 months)
Trial: 1492848
Drug: Flupirtine maleate
RxNorm normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine maleate 50 mg
Trial: 6342637
Drug: Flupirtine maleate
RxNorm normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine maleate 100 mg
Trial: 1492848
Drug: Flupirtine maleate
RxNorm normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine maleate 300 mg
Trial: 23765238
Drug: Adjuvant gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant gemcitabine chemotherapy
Trial: 22836057
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose radiation therapy (0.6 Gy in 6 fractions of 0.1 Gy twice weekly)
Trial: 22836057
Drug: Reirradiation (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reirradiation (standard dosage) offered to patients with insufficient pain relief after 3 months
Trial: 17988236
Drug: Tapering prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering prednisolone
Trial: 17988236
Drug: Predocol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predocol 40 mg/day
Trial: 17988236
Drug: Predocol 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predocol 60 mg/day
Trial: 12028242
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (37.5 to 225 mg/day)
Trial: 7138048
Drug: 0.1% anthralin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% anthralin combined with UV-B therapy
Trial: 7138048
Drug: 0.01% anthralin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% anthralin combined with UV-B therapy
Trial: 30302940
Drug: Pre-hospital administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital administration of ticagrelor
Trial: 30302940
Drug: In-hospital administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital administration of ticagrelor
Trial: 24144243
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light and melatonin capsules
Trial: 19176561
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin treatment (control)
Trial: 17660640
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate (40 mg/kg)
Trial: 558950
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg)
Trial: 17660640
Drug: Both drug
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drug regimens (chloral hydrate and diazepam)
Trial: 11598383
Drug: High insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin (15 mU/kg x min)
Trial: 11598383
Drug: Low insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low insulin (1.5 mU/kg x min)
Trial: 9594683
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 supplementation with isoniazid therapy
Trial: 9594683
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with isoniazid therapy
Trial: 25592341
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid treatment
Trial: 31068272
Drug: Bictegravir 50
RxNorm normalized name: bictegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg
Trial: 23038220
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (Dar), cumulative dose 11.1 µg/kg b.w. over 8 months
Trial: 12414848
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with daily injections of 0.4 mg GH/d (group A)
Trial: 12414848
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with 0.8 mg GH/d for 14 days every 3 months (group B)
Trial: 28188086
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (A and B)
Trial: 8681976
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of aminoglycosides
Trial: 1695801
Drug: Chemotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy group (89 patients) received Vincristine (1.5 mg/m2), Bleomycin (15 mg), Methotrexate (80 mg)
Trial: 1695801
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (chemotherapy and control)
Trial: 356761
Drug: Intermittent levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent levamisole therapy (150 mg daily for 3 days of each week)
Trial: 356761
Drug: Continuous levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous levamisole therapy (150 mg daily)
Trial: 3585450
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine sulfate (IRMS)
Trial: 16342193
Drug: Collection of
RxNorm normalized name: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collection of peripheral blood progenitor cells (PBPCs) on day 5 after G‐CSF administration.
Trial: 16342193
Drug: G‐CSF mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF mobilization of CD34(+) cells.
Trial: 10542895
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml 10% HES 200/0.5
Trial: 2312773
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg metoprolol CR/ZOK
Trial: 7010383
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cefaclor 3‐times daily (intermittent)
Trial: 7010383
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg amoxycillin 3‐times daily (continuous)
Trial: 30896743
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake (mean 886 mg/day)
Trial: 15494457
Drug: GnRH (gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH (gonadotropin-releasing hormone) bolus iv injection
Trial: 10455843
Drug: Buscopan 20
RxNorm normalized name: Buscopan 20 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan 20 mg
Trial: 2193555
Drug: 1-methadone (1.145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-methadone (1.145 mg)
Trial: 2193555
Drug: 1-methadone (0.573
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-methadone (0.573 mg) + metamizol (50 mg)
Trial: 19683731
Drug: Oral oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxybutynin
Trial: 19827464
Drug: 6.4% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% maltodextrin solution (CHO)
Trial: 2053765
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg sustained release verapamil as two divided doses
Trial: 6352209
Drug: Pulsed intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed intermittent subcutaneous insulin infusion (30‐, 60‐, and 120‐min intervals)
Trial: 30080693
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of prophylactic antibiotic drops (AB) each morning/evening
Trial: 30080693
Drug: Daily lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily lens cleaning (LC) each morning
Trial: 29072017
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (intravenous injection of aspartate ornithine and branched chain amino acids)
Trial: 9537455
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg of consensus interferon administered subcutaneously three times a week for 24 weeks
Trial: 9537455
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg of consensus interferon administered subcutaneously three times a week for 48 weeks
Trial: 7819467
Drug: Atropine 2
RxNorm normalized name: atropine 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 2 micrograms/kg administered in 60 sec. intervals up to a total dose of 10 micrograms/kg
Trial: 2458264
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of trypsin (150 mg h‐1; 1.25 g l‐1)
Trial: 2458264
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of aprotinin (1.5 X 10(6) KIU for 30 min)
Trial: 2458264
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of trypsin (300 mg h‐1; 2.5 g l‐1)
Trial: 21389180
Drug: High-protein and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein and moderate-carbohydrate diet (HPMC; 139 g protein, 82 g fat, 181 g carbohydrate/d)
Trial: 21389180
Drug: High-protein and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein and low-carbohydrate diet (HPLC; 137 g protein, 143 g fat, 22 g carbohydrate/d)
Trial: 21389180
Drug: Weight-maintenance diet
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-maintenance diet (85 g protein, 116 g fat, 360 g carbohydrate/d)
Trial: 11849198
Drug: SJW (0.15%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW (0.15%) 600 mg three times daily for 16 days
Trial: 2185350
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of risk factors (specific interventions not detailed)
Trial: 463804
Drug: Corn syrup
RxNorm normalized name: Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn syrup diets (45% of total energy)
Trial: 463804
Drug: Corn syrup
RxNorm normalized name: Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn syrup diets (65% of total energy)
Trial: 23352229
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (16IU)
Trial: 2879389
Drug: Celiprolol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (300 mg for 4 weeks)
Trial: 2879389
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg for 4 weeks)
Trial: 25319061
Drug: Abituzumab 500
RxNorm normalized name: sacituzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abituzumab 500 mg combined with cetuximab and irinotecan (arm A)
Trial: 25319061
Drug: Abituzumab 1000
RxNorm normalized name: obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abituzumab 1000 mg combined with cetuximab and irinotecan (arm B)
Trial: 21889560
Drug: Switching group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching group (paroxetine 20-40 mg)
Trial: 17444378
Drug: Polarised light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polarised light treatment (once daily for 10 minutes on sacral area and both heels)
Trial: 8506453
Drug: Gammahydroxybutyrate (GHB),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gammahydroxybutyrate (GHB), 60 mg/kg/night
Trial: 3829910
Drug: Ascot preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascot preparation of procainamide hydrochloride
Trial: 3829910
Drug: Squibb preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squibb preparation of procainamide hydrochloride
Trial: 2575983
Drug: epanolol 200mg
RxNorm normalized name: epanolol
DrugBank: Epanolol (DB13757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol 200mg once daily
Trial: 2575982
Drug: metoprolol 100mg
RxNorm normalized name: HCTZ 25/METOPROLOL 100MG TAB
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoprolol 100mg twice daily
Trial: 28390289
Drug: Lenvatinib 24
RxNorm normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 24 mg orally once daily
Trial: 23735418
Drug: Low intracellular
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intracellular magnesium (iMg) levels (<3.75 mg/dL erythrocytes)